The consolidated guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management, adapted to the national and local epidemiology of TB, the availability of resources, the health infrastructure and other national and local determinants. The gu...idelines are to be used primarily in national TB and HIV control programmes, or their equivalents in ministries of health, and for other policy-makers working on TB and HIV and infectious diseases. They are also appropriate for officials in other line ministries with work in the areas of health.
more
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Цей документ описує кроки, необхідні для визначення скоригованого інтервалу QT (QTc) в
ході моніторингу ЕКГ пацієнтів, які отримують препарати для лікування ХР ТБ, що... викликають пролонгацію інтервалу QT. Він також надає рекомендації щодо ведення випадків пролонгації QTc.
more
INT J TUBERC LUNG DIS 22(2):197–205 http://dx.doi.org/10.5588/ijtld.17.0245
One key aim of tuberculosis (TB) prevention and care is to render them more people-centred, which means further boosting and improving ambulatory care models across the countries of Eastern Europe and central Asia. This note is intended to remind interested parties of the evidence that shows that am...bulatory care is both feasible and safe
more
Este documento presenta modelos de algoritmos que permiten investigar por métodos bacteriológicos a los pacientes para el diagnóstico de tuberculosis (TB), TB asociada al Virus de Inmunodeficiencia Humana (TB-HIV) y TB drogorresistente (TBDR).
Healthy me, healthy us: a guide for community members about good health and staying healthy with chronic illness
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Информация о туберкулезной терапии для больных и их родственников
La stratégie FAST peut être utilisée pour réduire la propagation de la tuberculose ou de la tuberculose mul- tirésistante dans les environnements suivants : les hôpitaux, les cliniques, les prisons et d’autres types d’établissement tels que les centres d’accueil pour sans abri ou les ca...mps de réfugiés.
more
Regional snapshot: Eastern Europe and Central Asia
December 2018
https://data.unicef.org/wp-content/uploads/2018/11/EECA-regional-snapshot-2018.pdf
Assurer des prestations optimales dans la chaîne de soins destinés aux patients tuberculeux
Deuxième édition - Juin 2018
Презентация на тему диагностики туберкулеза
Este rotafolio es un material didáctico, ilustrado, importante para la labor que realiza el personal del sector de la salud, llámense auxiliares de enfermería, agentes comunitarios de salud, promotores de salud, entre otros, para la
divulgación y apropiación de los conceptos básicos de la TUB...ERCULOSIS, ya sea durante la visita domiciliaria o durante las actividades con las instituciones de salud de su zona u otras organizaciones, mediante acciones dirigidas a la prevención y el control de esta enfermedad.
more
In 2017, 3.6 million of the estimated 10 million people with TB worldwide were “missed” by national TB programmes (NTPs). Two thirds of them are thought to access TB treatment of questionable quality from public and private providers who are not engaged by the NTP. The quality of care provided i...n these settings is often not known or substandard. Closing these gaps and ensuring patient-centred care imply that quality-assured and affordable TB services must be made available wherever people choose to seek care.
more
This report presents an overview of the transition process in Azerbaijan, some sustainability aspects and challenges stemming from donor withdrawal from TB-related activities, along with recommendations on how to overcome transition-related difficulties and ensure sustainability.
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
